Treatment

Source: Chapter 3 in full. Section numbering and the part’s own reference list retained from the source chapter.

The clinical response: acute, bridge and preventive treatment, neuromodulation and surgery — and the country-by-country access realities that often decide more than the evidence does.

Compiled as a personal reference document. Every claim below carries an evidence tag: peer-reviewed, preprint / trial, citizen science, community report, or historical. Community reports are never discarded for being anecdotal — they are labelled honestly and included because patterns in anecdote are data. Where sources conflict, the conflict is presented explicitly rather than smoothed over. “Unknown” and “contested” are treated as valid, final answers where that is what the evidence supports.

This chapter covers acute/abortive treatment, transitional/bridge therapy, preventive treatment, neuromodulation and surgical procedures, and country-by-country access realities — with particular attention to Australia, and South Australia specifically. It draws on peer-reviewed trials and meta-analyses, registered trials and preprints, structured citizen-science surveys, community reports from r/clusterheads and r/ClusterHeadaches, and non-English clinical literature and guidelines from Germany, Denmark, Japan, Italy, and elsewhere, sourced and cross-checked over four dedicated research passes covering roughly 280 unique sources between them.

The single most important pattern threading through everything below: chronic cluster headache is worse-served by the evidence base than episodic cluster headache, on almost every treatment, at almost every level of evidence. Where trials report a chronic subgroup at all, it almost always does worse than the episodic group — sometimes dramatically so. Readers with chronic daily CH should discount headline efficacy figures accordingly unless a section explicitly says otherwise.

---

1. Acute / Abortive Treatment

Acute treatment aims to shorten or stop an individual attack. Because chronic sufferers face attacks daily, sometimes several times a day, the ceiling on how often each acute option can be used safely is as important as its per-attack efficacy — and is where community practice and formal guidance diverge most sharply.